2024-516670-29-00招募中2 期
ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 17
- 主要终点
- MRD 10-5 incidence rate determined (as the best response obtained at any time point during treatment) as per IMWG criteria by NGS (centrally performed, Pr Avet Loiseau Toulouse Oncopole).
研究概览
简要总结
The primary objective is to determine the efficacy of IsPd + K in early Relapse Refractory Multiple Myeloma according to IMWG*.
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Must be able to understand and voluntarily sign an informed consent form
- •Adequate organ function defined as: o Serum total bilirubin < 2x upper limit of normal (ULN), o Clearance creatinine ≥ 30ml/min, o Serum SGOT/AST or SGPT/ALT < 3x upper limit of normal (ULN).
- •Patients affiliated to an appropriate social security system.
- •A man who is sexually active with a pregnant female or a FCBP* must agree to use a barrier method of birth control eg, condom with spermicidal foam/gel/film/cream/suppository, even if he has had a vasectomy. All men must also not donate sperm, spermatozoa during the study, for 5 months following treatment discontinuation.
- •A woman FCBP* must understand and agree to use 2 reliable effective methods (a very effective method and an effective additional method) of contraception simultaneously without interruption: o For at least 28 days before starting experimental treatments o Throughout the entire duration of experimental treatments, o During dose interruptions, o And for at least 5 months after the last dose of experimental treatments.
- •All patients must agree to not donate blood during the treatment period, interruptions of treatment and at least 5 months after the last dose of treatment
- •All patients must understand and accept to comply with the conditions of the Pomalidomide pregnancy prevention plan (Appendix of the protocol).
- •Must be able to adhere to the study visit schedule and other protocol requirements
- •Male or female, age 18 years or older
- •Life expectancy of > 6 months.
- •Must be in R1 (Line 2) and R2 (Line 3) relapse Multiple Myeloma with a measurable disease o Have had 1 to maximum 2 lines of therapy prior to study entry o Relapse Refractory or primary refractory or relapse o Must have received prior treatment with a Lenalidomide-containing regimen for at least 2 consecutive cycles
- •Must have measurable disease as defined by the following: must have a clearly detectable and quantifiable monoclonal M-component value in the serum and/or urine. o IgG/IgA (serum M-component > 5g/l), o Light chain (serum M-component >1g/l or Bence Jones > 200mg/24H), o Serum FLC assay (including for IgD isotypes): involved FLC level > 10 mg/dl provided serum. FLC ratio is abnormal for patients not measurable on any of the 3 above criteria.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
- •Wash out period without MM treatment must be of 28 days minimum before C1D1, except for anti CD-38 (See exclusion criteria#10).
- •Adequate bone marrow function, documented within 72 hours and without transfusion 72 hours prior to the first intake of investigational product (C1J1) with no growth factor support (one week), defined as: o Absolute neutrophils ≥ 1 x109/L, o Untransfused Platelet count ≥ 75 x109/L, o Hemoglobin ≥ 8.5 g/dL.
排除标准
- •Any other uncontrolled medical condition or comorbidity that might interfere with subject’s participation, including simultaneous participation to another interventional clinical study.
- •Refractory to prior anti CD
- •Patients can be exposed to anti CD38 (any), BUT the wash out period for patient pre-treated with an anti CD38 antibody must be of 4,5 months minimum between last dose of previous anti-CD38 antibody and the first dose of isatuximab.
- •Refractory to prior carfilzomib.
- •Known allergy to one of the study product (pomalidomide, isatuximab, carfilzomib) or dexamethasone
- •Patient with a history of severe allergic reactions to thalidomide or lenalidomide
- •Previously exposed to pomalidomide
- •Known intolerance to infused protein products, sucrose, histidine, and polysorbate 80
- •Contraindications to dexamethasone
- •Any ongoing non hematological adverse event grade > 2 severity or medical history grade > 2 severity
- •Pregnant or breast-feeding females
- •Refusal to participate in the study
- •Known positive for HIV or active infectious hepatitis, type B or C.
- •Persons protected by a legal regime (guardianship, trusteeship)
- •Patients with non-secretory MM and non-measurable MM
- •Patient with terminal renal failure that require dialysis or clearance creatinine < 30 ml/min (calculated with MDRD formula)
- •Any uncontrolled or severe cardiovascular or pulmonary disease determined by the investigator including: o NYHA functional classification III or IV congestive heart failure o LVEF (Left Ventricular Ejection Fraction) < 40% o Uncontrolled angina, hypertension or arrhythmia o Myocardial infarction in the past 6 months
- •Prior history of malignancies, other than multiple myeloma, unless the patients has been free of the disease for ≥ 5 years. Exceptions include the following: o Basal or squamous cell carcinoma of the skin o Carcinoma in situ of the cervix or breast o Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
- •Evidence of central nervous system (CNS) involvement
- •Ongoing active infection or other clinically significant uncontrolled cardiovascular events
- •Unable to comply with IMids regulation to thromboprophylaxis, or teratogenic recommendations.
结局指标
主要结局
MRD 10-5 incidence rate determined (as the best response obtained at any time point during treatment) as per IMWG criteria by NGS (centrally performed, Pr Avet Loiseau Toulouse Oncopole).
MRD 10-5 incidence rate determined (as the best response obtained at any time point during treatment) as per IMWG criteria by NGS (centrally performed, Pr Avet Loiseau Toulouse Oncopole).
次要结局
- Time to response and Response duration for responders as per IMWG criteria.
- Treatment emergent adverse events of IsPd +K will be evaluated according to CTCAE 5.0.
- To determine Overall Response Rate (ORR, Partial Response and better), Very Good Partial Response (VGPR) + CR rate of IsPd +K as per IMWG criteria and with M protein interference testing. Clinical benefit response rate (CBR, Minor Response (MR) and better) of IsPd +K as per IMWG criteria.
- Overall Survival (OS), Progression free survival (PFS), Time To Progression (TTP), Time To Next Therapy (TTNT) and Event Free survival (EFS) of IsPd +K will be evaluated as per IMWG criteria.
研究者
Coordinating investigator
Scientific
Centre Hospitalier Universitaire De Poitiers
研究点 (17)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaHaematological malignancyMedDRA version: 19.0Level: PTClassification code 10042987Term: T-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10036543Term: Precursor T-lymphoblastic lymphoma/leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002739-14-LTSanofi-aventis recherche & développement43
进行中（未招募）
1 期
Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaHaematological malignancyMedDRA version: 19.0Level: PTClassification code 10042987Term: T-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10036543Term: Precursor T-lymphoblastic lymphoma/leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002739-14-HUSanofi-aventis recherche & développement39
进行中（未招募）
1 期
Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaMedDRA version: 21.1Level: PTClassification code 10036543Term: Precursor T-lymphoblastic lymphoma/leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10042987Term: T-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)CancerEUCTR2016-002739-14-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT14
进行中（未招募）
1 期
Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaHaematological malignancyMedDRA version: 19.0Level: PTClassification code 10042987Term: T-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10036543Term: Precursor T-lymphoblastic lymphoma/leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002739-14-FISanofi-aventis recherche & développement43
进行中（未招募）
1 期
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairmentnewly diagnosed patients with multiple myeloma and severe renal impairmentMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2021-004895-32-GRHellenic Society of Hematology (EAE)51